Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.
Follow ADAPY
Adaptimmune Therapeutics PLC (ADAPY) Piotroski F-score
Adaptimmune Therapeutics PLC's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 0.00 |
| FY2024 | 4 | 1.00 |
| FY2023 | 3 | 1.00 |
| FY2022 | 2 | (3.00) |
| FY2021 | 5 | 0.00 |
| FY2020 | 5 | 4.00 |
| FY2019 | 1 | (2.00) |
| FY2018 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 16.27% | (27.17%) | Pass | 1 |
| Positive operating cash flow | (121.91m) | (69.11m) | Fail | 0 |
| Rising return on assets | 16.27% | (27.17%) | Pass | 1 |
| Cash flow above net income | (147.11m) | 2.77m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.19 | Pass | 1 |
| Rising current ratio | 2.04 | 2.88 | Fail | 0 |
| No new shares issued | 262,832,000 | 252,302,000 | Fail | 0 |
| Rising gross margin | 100.00% | 99.96% | Pass | 1 |
| Rising asset turnover | 0.04 | 0.67 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ADAPY Adaptimmune Therapeutics PLC | 4 |
| BCDA BioCardia, Inc. compare | 4 |
| DARE Dare Bioscience, Inc. compare | 4 |
| CLVSQ Clovis Oncology, Inc. compare | 3 |
| CNSY Cerenome, Inc. compare | 3 |
| RVLP RVL Pharmaceuticals PLC compare | 3 |
| TVRD Tvardi Therapeutics, Inc. compare | 3 |
| LPCN Lipocine Inc. compare | 1 |
| GTBP GT Biopharma, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover